Clinical Trial Update: A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating CG-806 in patients with relapsed or refractory acute myeloid leukemia or higher-risk myelodysplastic syndromes has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• CG-806

Snippet

Sponsor: Aptose Biosciences Inc. | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Status: TERMINATED